Advertisement

Drugs

, Volume 74, Issue 16, pp 1871–1889 | Cite as

Patient-Centered Pharmaceutical Design to Improve Acceptability of Medicines: Similarities and Differences in Paediatric and Geriatric Populations

  • Fang Liu
  • Sejal Ranmal
  • Hannah K. Batchelor
  • Mine Orlu-Gul
  • Terry B. Ernest
  • Iwan W. Thomas
  • Talia Flanagan
  • Catherine Tuleu
Review Article

Abstract

Patient acceptability of a medicinal product is a key aspect in the development and prescribing of medicines. Children and older adults differ in many aspects from the other age subsets of population and require particular considerations in medication acceptability. This review highlights the similarities and differences in these two age groups in relation to factors affecting acceptability of medicines. New and conventional formulations of medicines are considered regarding their appropriateness for use in children and older people. Aspects of a formulation that impact acceptability in these patient groups are discussed, including, for example, taste/smell/viscosity of a liquid and size/shape of a tablet. A better understanding of the acceptability of existing formulations highlights opportunities for the development of new and more acceptable medicines and facilitates safe and effective prescribing for the young and older populations.

Keywords

Dosage Form Oropharyngeal Dysphagia Solid Dosage Form Sour Taste Chewable Tablet 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Supplementary material

40265_2014_297_MOESM1_ESM.docx (36 kb)
Supplementary material 1 (DOCX 35 kb)

References

  1. 1.
    Kozarewicz P. Regulatory perspectives on acceptability testing of dosage forms in children. Int J Pharm. 2014;469:245–8.PubMedCrossRefGoogle Scholar
  2. 2.
    Paradiso LM, Roughead EE, Gilbert AL, et al. Crushing or altering medications: what’s happening residential aged-care facilities? Australas J Ageing. 2002;21:123–1270.CrossRefGoogle Scholar
  3. 3.
    Cuzzolin L, Atzei A, Fanos V. Off-label and unlicensed prescribing for newborns and children in different settings: a review of the literature and a consideration about drug safety. Expert Opin Drug Saf. 2006;5:703–18.PubMedCrossRefGoogle Scholar
  4. 4.
    Richey RH, Shah UU, Peak M, et al. Manipulation of drugs to achieve the required dose is intrinsic to paediatric practice but is not supported by guidelines or evidence. BMC Pediatr. 2013;13:81.PubMedPubMedCentralCrossRefGoogle Scholar
  5. 5.
    Standing JF, Tuleu C. Paediatric formulations—getting to the heart of the problem. Int J Pharm. 2005;300:56–66.PubMedCrossRefGoogle Scholar
  6. 6.
    Wright D. Medication administration in nursing homes. Nurs Stand. 2002;16:33–8.PubMedCrossRefGoogle Scholar
  7. 7.
    European Medicines Agency (EMA). Guideline on pharmaceutical development of medicines for paediatric use 2011. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2011/06/WC500107908.pdf. Accessed 11 Jul 2014.
  8. 8.
    European Medicines Agency (EMA). Concept paper on the need of a reflection paper on the quality requirements of medicines for older adults, 2013. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2014/01/WC500159545.pdf. Accessed 11 Sep 2014.
  9. 9.
    Hajjar ER, Cafiero AC, Hanlon JT. Polypharmacy in elderly patients. Am J Geriatr Pharmacother. 2007;5:345–51.PubMedCrossRefGoogle Scholar
  10. 10.
    Claxton AJ, Cramer J, Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin Ther. 2001;23:1296–310.PubMedCrossRefGoogle Scholar
  11. 11.
    Salzman C. Medication compliance in the elderly. J Clin Psychiatry. 1995;56(Suppl 1):18–22 (discussion 23).PubMedGoogle Scholar
  12. 12.
    Bernabei R, Rossini PM, Di Cioccio L, et al. Compliance and caregiver satisfaction in Alzheimer’s disease: results from the AXEPT Study. Dement Geriatr Cogn Dis Extra. 2012;2:418–32.PubMedPubMedCentralCrossRefGoogle Scholar
  13. 13.
    Cloyd JC, Kriel RL, Jones-Saete CM, et al. Comparison of sprinkle versus syrup formulations of valproate for bioavailability, tolerance, and preference. J Pediatr. 1992;120:634–8.PubMedCrossRefGoogle Scholar
  14. 14.
    Motte J, Pedespan JM, Sevestre M, et al. Acceptability and tolerance of sodium valproate, a new sustained-action granule formulation, in monotherapy for epileptic children from 3 years old [in French]. Arch Pediatr. 2005;12:1533–9.PubMedCrossRefGoogle Scholar
  15. 15.
    Sevilla C, Jimenez Caballero PE, Alfonso V, et al. Current treatments of Alzheimer disease: are main caregivers satisfied with the drug treatments received by their patients? Dement Geriatr Cogn Disord. 2009;28:196–205.PubMedCrossRefGoogle Scholar
  16. 16.
    Jefferds MED, Ogange L, Owuor M, et al. Formative research exploring acceptability, utilization, and promotion in order to develop a micronutrient powder (Sprinkles) intervention among Luo families in western Kenya. Food Nutr Bull. 2010;31:S179–85.PubMedCrossRefGoogle Scholar
  17. 17.
    European Medicines Agency (EMA). Guideline on pharmaceutical development of medicines for paediatric use. 2013. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2013/07/WC500147002.pdf. Accessed 18 Sep 2014.
  18. 18.
    Stegemann S, Gosch M, Breitkreutz J. Swallowing dysfunction and dysphagia is an unrecognized challenge for oral drug therapy. Int J Pharm. 2012;430:197–206.PubMedCrossRefGoogle Scholar
  19. 19.
    Kramer SS, Eicher PM. The evaluation of pediatric feeding abnormalities. Dysphagia. 1993;8:215–24.PubMedCrossRefGoogle Scholar
  20. 20.
    Foy TM, Czyzewski DI. Feeding difficulties. In: Duggan CW, Watkins JB, Walker WA, editors. Nutrition in pediatrics: basic science, clinical applications. Hamilton: BC Decker; 2008.Google Scholar
  21. 21.
    Lefton-Greif MA, Arvedson JC. Pediatric feeding and swallowing disorders: State of health, population trends, and application of the International Classification of Functioning, Disability, and Health. Semin Speech Lang. 2007;28:161–5.PubMedCrossRefGoogle Scholar
  22. 22.
    Prasse JE, Kikano GE. An overview of pediatric dysphagia. Clin Pediatr (Phila). 2009;48:247–51.CrossRefGoogle Scholar
  23. 23.
    Kakodkar K, Schroeder JW. Pediatric dysphagia. Pediatr Clin North Am. 2013;60:969–77.PubMedCrossRefGoogle Scholar
  24. 24.
    Arvedson JC. Assessment of pediatric dysphagia and feeding disorders: clinical and instrumental approaches. Dev Disabil Res Rev. 2008;14:118–27.PubMedCrossRefGoogle Scholar
  25. 25.
    Khan A, Carmona R, Traube M. Dysphagia in the elderly. Clin Geriatr Med. 2014;30:43–53.PubMedCrossRefGoogle Scholar
  26. 26.
    Kelly J, Wright D. Administering medication to adult patients with dysphagia. Nurs Stand. 2009;23:62–8.PubMedCrossRefGoogle Scholar
  27. 27.
    Steele CM, Greenwood C, Ens I, et al. Mealtime difficulties in a home for the aged: not just dysphagia. Dysphagia. 1997;12:45–50.CrossRefGoogle Scholar
  28. 28.
    Easterling C, Robbins E. Dementia and dysphagia. Geriatr Nurs. 2008;29:275–85.PubMedCrossRefGoogle Scholar
  29. 29.
    Crary MA, Humphrey JL, Carnaby-Mann G, et al. Dysphagia, nutrition, and hydration in ischemic stroke patients at admission and discharge from acute care. Dysphagia. 2013;28:69–76.PubMedCrossRefGoogle Scholar
  30. 30.
    Gordon C, Hewer RL, Wade DT. Dysphagia in acute stroke. Br Med J (Clin Res Ed). 1987;295:411–4.CrossRefGoogle Scholar
  31. 31.
    Eggenberger SK, Nelms TP. Artificial hydration and nutrition in advanced Alzheimer’s disease: facilitating family decision-making. J Clin Nurs. 2004;13:661–7.PubMedCrossRefGoogle Scholar
  32. 32.
    Committee for Medicinal Products for Human Use (CHMP). Reflection paper: formulations of choice for the paediatric population. 2006. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003782.pdf. Accessed 11 Sep 2014.
  33. 33.
    Yeung VW, Wong ICK. When do children convert from liquid antiretroviral to solid formulations? Pharm World Sci. 2005;27:399–402.PubMedCrossRefGoogle Scholar
  34. 34.
    Nahirya-Ntege P, Cook A, Vhembo T, et al. Young HIV-infected children and their adult caregivers prefer tablets to syrup antiretroviral medications in Africa. PLoS One. 2012;7:e36186.PubMedPubMedCentralCrossRefGoogle Scholar
  35. 35.
    Babbitt RL, Parrish JM, Brierley PE, et al. Teaching developmentally disabled children with chronic illness to swallow prescribed capsules. J Dev Behav Pediatr. 1991;12:229–35.PubMedCrossRefGoogle Scholar
  36. 36.
    Beck MH, Cataldo M, Slifer KJ, et al. Teaching children with attention deficit hyperactivity disorder (ADHD) and autistic disorder (AD) how to swallow pills. Clin Pediatr (Phila). 2005;44:515–26.CrossRefGoogle Scholar
  37. 37.
    Czyzewski D, Runyan D, Lopez M, et al. Teaching and maintaining pill swallowing in HIV-infected children. AIDS Read. 2000;10:88–94.Google Scholar
  38. 38.
    Garvie PA, Lensing S, Rai SN. Efficacy of a pill-swallowing training intervention to improve antiretroviral medication adherence in pediatric patients with HIV/AIDS. Pediatrics. 2007;119:E893–9.PubMedCrossRefGoogle Scholar
  39. 39.
    Ghuman JK, Cataldo MD, Beck MH, et al. Behavioral training for pill-swallowing difficulties in young children with autistic disorder. J Child Adolesc Psychopharmacol. 2004;14:601–11.PubMedCrossRefGoogle Scholar
  40. 40.
    Kaplan BJ, Steiger RA, Pope J, et al. Successful treatment of pill-swallowing difficulties with head posture practice. Paediatr Child Health. 2010;15:e1–5.PubMedPubMedCentralCrossRefGoogle Scholar
  41. 41.
    Meltzer EO, Welch MJ, Ostrom NK. Pill swallowing ability and training in children 6 to 11 years of age. Clin Pediatr (Phila). 2006;45:725–33.CrossRefGoogle Scholar
  42. 42.
    Steffensen GK, Pachai A, Pedersen SE. Peroral drug administration to children—are there any problems? Ugeskr Laeger. 1998;160:2249–52.PubMedGoogle Scholar
  43. 43.
    Hansen DL, Tulinius D, Hansen EH. Adolescents’ struggles with swallowing tablets: barriers, strategies and learning. Pharm World Sci. 2008;30:65–9.PubMedCrossRefGoogle Scholar
  44. 44.
    Polaha J, Dalton WT III, Lancaster BM. Parental report of medication acceptance among youth: implications for everyday practice. South Med J. 2008;101:1106–12.PubMedCrossRefGoogle Scholar
  45. 45.
    Hommel KA, Baldassano RN. Brief report: barriers to treatment adherence in pediatric inflammatory bowel disease. J Pediatr Psychol. 2010;35:1005–10.PubMedCrossRefGoogle Scholar
  46. 46.
    Modi AC, Quittner AL. Barriers to treatment adherence for children with cystic fibrosis and asthma: what gets in the way? J Pediatr Psychol. 2006;31:846–58.PubMedCrossRefGoogle Scholar
  47. 47.
    Modi AC, Zeller MH, Xanthakos SA, et al. Adherence to vitamin supplementation following adolescent bariatric surgery. Obesity. 2013;21:E190–5.PubMedPubMedCentralCrossRefGoogle Scholar
  48. 48.
    Schirm E, Tobi H, de Vries TW, et al. Lack of appropriate formulations of medicines for children in the community. Acta Paediatr. 2003;92:1486–9.PubMedCrossRefGoogle Scholar
  49. 49.
    Tissen C, Woertz K, Breitkreutz J, et al. Development of mini-tablets with 1 mm and 2 mm diameter. Int J Pharm. 2011;416:164–70.PubMedCrossRefGoogle Scholar
  50. 50.
    Kokki H, Nikanne E, Ahonen R. The feasibility of pain treatment at home after adenoidectomy with ketoprofen tablets in small children. Paediatr Anaesth. 2000;10:531–5.PubMedCrossRefGoogle Scholar
  51. 51.
    Kreeftmeijer-Vegter AR, de Meijer M, Wegman KA, et al. Development and evaluation of age-appropriate film-coated tablets of levamisole for paediatric use (2–18 years). Expert Opin Drug Deliv. 2013;10:293–300.PubMedCrossRefGoogle Scholar
  52. 52.
    Thomson SA, Tuleu C, Wong ICK, et al. Minitablets: new modality to deliver medicines to preschool-aged children. Pediatrics. 2009;123:E235–8.PubMedCrossRefGoogle Scholar
  53. 53.
    Klingmann V, Spomer N, Lerch C, et al. Favorable acceptance of mini-tablets compared with syrup: a randomized controlled trial in infants and preschool children. J Pediatr. 2013;163:1728–32.PubMedCrossRefGoogle Scholar
  54. 54.
    Van de Vijver E, Desager K, Mulberg AE, et al. Treatment of infants and toddlers with cystic fibrosis-related pancreatic insufficiency and fat malabsorption with pancrelipase MT. J Pediatr Gastroenterol Nutr. 2011;53:61–4.PubMedCrossRefGoogle Scholar
  55. 55.
    van Riet-Nales DA, de Neef BJ, Schobben AFAM, et al. Acceptability of different oral formulations in infants and preschool children. Arch Dis Child. 2013;98:725–31.PubMedPubMedCentralCrossRefGoogle Scholar
  56. 56.
    Strachan I, Greener M. Medication-related swallowing difficulties may be more common than we realise. Pharm Pract. 2005;15:411–4.Google Scholar
  57. 57.
    Schiele JT, Quinzler R, Klimm HD, et al. Difficulties swallowing solid oral dosage forms in a general practice population: prevalence, causes, and relationship to dosage forms. Eur J Clin Pharmacol. 2013;69:937–48.PubMedCrossRefGoogle Scholar
  58. 58.
    Marquis J, Schneider MP, Payot V, et al. Swallowing difficulties with oral drugs among polypharmacy patients attending community pharmacies. Int J Clin Pharm. 2013;35:1130–6.PubMedCrossRefGoogle Scholar
  59. 59.
    Hind JA, Nicosia MA, Roecker EB, et al. Comparison of effortful and noneffortful swallows in healthy middle-aged and older adults. Arch Phys Med Rehabil. 2001;82:1661–5.PubMedCrossRefGoogle Scholar
  60. 60.
    Nagaya M, Kachi T, Yamada T. Effect of swallowing training on swallowing disorders in Parkinson’s disease. Scand J Rehabil Med. 2000;32:11–5.PubMedCrossRefGoogle Scholar
  61. 61.
    Kelly J, D’Cruz G, Wright D. Patients with dysphagia: experiences of taking medication. J Adv Nurs. 2010;66:82–91.PubMedCrossRefGoogle Scholar
  62. 62.
    Kikendall JW. Pill-induced esophageal injury. Gastroenterol Clin North Am. 1991;20:835–46.PubMedGoogle Scholar
  63. 63.
    Delwiche J. The impact of perceptual interactions on perceived flavor. Food Qual Prefer. 2004;15:137–46.CrossRefGoogle Scholar
  64. 64.
    Srivastava RK, More AT. Some aesthetic considerations for over the‐counter (OTC) pharmaceutical products. Int J Biotechnol. 2010;11:267–83.CrossRefGoogle Scholar
  65. 65.
    Kesselheim AS, Misono AS, Shrank WH, et al. Variations in pill appearance of antiepileptic drugs and the risk of nonadherence. JAMA Intern Med. 2013;173:202–8.PubMedCrossRefGoogle Scholar
  66. 66.
    Craen AJ, Roos PJ, Vries AL, et al. Effect of colour of drugs: systematic review of perceived effect of drugs and of their effectiveness. BMJ. 1996;313:1624–6.PubMedPubMedCentralCrossRefGoogle Scholar
  67. 67.
    Smith CJ, Sammons HM, Fakis A, et al. A prospective study to assess the palatability of analgesic medicines in children. J Adv Nurs. 2013;69:655–63.PubMedCrossRefGoogle Scholar
  68. 68.
    Overgaard AB, Hojsted J, Hansen R, et al. Patients’ evaluation of shape, size and colour of solid dosage forms. Pharm World Sci. 2001;23:185–8.PubMedCrossRefGoogle Scholar
  69. 69.
    Hey H, Jorgensen F, Sorensen K, et al. Oesophageal transit of six commonly used tablets and capsules. Br Med J (Clin Res Ed). 1982;285:1717–9.CrossRefGoogle Scholar
  70. 70.
    Suiter DM, Leder SB. Clinical utility of the 3-ounce water swallow test. Dysphagia. 2008;23:244–50.PubMedCrossRefGoogle Scholar
  71. 71.
    Uloza V, Uloziene I, Gradauskiene E. A randomized cross-over study to evaluate the swallow-enhancing and taste-masking properties of a novel coating for oral tablets. Pharm World Sci. 2010;32:420–3.PubMedCrossRefGoogle Scholar
  72. 72.
    Diamond S, Lavallee DC. Experience with a pill-swallowing enhancement aid. Clin Pediatr (Phila). 2010;49:391–3.CrossRefGoogle Scholar
  73. 73.
    Yamamoto S, Taniguchi H, Hayashi H, et al. How do tablet properties influence swallowing behaviours? J Pharm Pharmacol. 2013;66:32–9.PubMedCrossRefGoogle Scholar
  74. 74.
    Channer KS, Virjee JP. The effect of formulation on oesophageal transit. J Pharm Pharmacol. 1985;37:126–9.PubMedCrossRefGoogle Scholar
  75. 75.
    Channer KS, Virjee JP. The effect of size and shape of tablets on their esophageal transit. J Clin Pharmacol. 1986;26:141–6.PubMedCrossRefGoogle Scholar
  76. 76.
    Robertson CS, Hardy JG. Oesophageal transit of small tablets. J Pharm Pharmacol. 1988;40:595–6.PubMedCrossRefGoogle Scholar
  77. 77.
    Perkins AC, Wilson CG, Blackshaw PE, et al. Impaired oesophageal transit of capsule versus tablet formulations in the elderly. Gut. 1994;35:1363–7.PubMedPubMedCentralCrossRefGoogle Scholar
  78. 78.
    Perkins AC, Wilson CG, Frier M, et al. Esophageal transit of risedronate cellulose-coated tablet and gelatin capsule formulations. Int J Pharm. 1999;186:169–75.PubMedCrossRefGoogle Scholar
  79. 79.
    Evans KT, Roberts GM. The ability of patients to swallow capsules. J Clin Hosp Pharm. 1981;6:207–8.PubMedGoogle Scholar
  80. 80.
    Channer KS, Virjee J. Effect of posture and drink volume on the swallowing of capsules. Br Med J (Clin Res Ed). 1982;285:1702.CrossRefGoogle Scholar
  81. 81.
    Osmanoglou E, Van Der Voort IR, Fach K, et al. Oesophageal transport of solid dosage forms depends on body position, swallowing volume and pharyngeal propulsion velocity. Neurogastroenterol Motil. 2004;16:547–56.PubMedCrossRefGoogle Scholar
  82. 82.
    Bailey RT Jr, Bonavina L, McChesney L, et al. Factors influencing the transit of a gelatin capsule in the esophagus. Drug Intell Clin Pharm. 1987;21:282–5.PubMedCrossRefGoogle Scholar
  83. 83.
    Butler SG, Stuart A, Leng X, et al. Factors influencing aspiration during swallowing in healthy older adults. Laryngoscope. 2010;120:2147–52.PubMedPubMedCentralCrossRefGoogle Scholar
  84. 84.
    Lundy DS, Smith C, Colangelo L, et al. Aspiration: cause and implications. Otolaryngol Head Neck Surg. 1999;120:474–8.PubMedCrossRefGoogle Scholar
  85. 85.
    Chee C, Arshad S, Singh S, et al. The influence of chemical gustatory stimuli and oral anaesthesia on healthy human pharyngeal swallowing. Chem Senses. 2005;30:393–400.PubMedCrossRefGoogle Scholar
  86. 86.
    Ding R, Logemann JA, Larson CR, et al. The effects of taste and consistency on swallow physiology in younger and older healthy individuals: a surface electromyographic study. J Speech Lang Hear Res. 2003;46:977–89.PubMedCrossRefGoogle Scholar
  87. 87.
    Logemann JA, Pauloski BR, Colangelo L, et al. Effects of a sour bolus on oropharyngeal swallowing measures in patients with neurogenic dysphagia. J Speech Hear Res. 1995;38:556–63.PubMedCrossRefGoogle Scholar
  88. 88.
    Miura Y, Morita Y, Koizumi H, et al. Effects of taste solutions, carbonation, and cold stimulus on the power frequency content of swallowing submental surface electromyography. Chem Senses. 2009;34:325–31.PubMedCrossRefGoogle Scholar
  89. 89.
    Pelletier CA, Dhanaraj GE. The effect of taste and palatability on lingual swallowing pressure. Dysphagia. 2006;21:121–8.PubMedCrossRefGoogle Scholar
  90. 90.
    Alves LM, Secaf M, Dantas RO. Effect of a bitter bolus on oral, pharyngeal and esophageal transit of healthy subjects. Arq Gastroenterol. 2013;50:31–4.PubMedCrossRefGoogle Scholar
  91. 91.
    Pelletier CA, Lawless HT. Effect of citric acid and citric acid–sucrose mixtures on swallowing in neurogenic oropharyngeal dysphagia. Dysphagia. 2003;18:231–41.PubMedCrossRefGoogle Scholar
  92. 92.
    Cola PC, Gatto AR, Silva RG, et al. The influence of sour taste and cold temperature in pharyngeal transit duration in patients with stroke. Arq Gastroenterol. 2010;47:18–21.PubMedCrossRefGoogle Scholar
  93. 93.
    Michou E, Mastan A, Ahmed S, et al. Examining the role of carbonation and temperature on water swallowing performance: a swallowing reaction-time study. Chem Senses. 2012;37:799–807.PubMedCrossRefGoogle Scholar
  94. 94.
    Sdravou K, Walshe M, Dagdilelis L. Effects of carbonated liquids on oropharyngeal swallowing measures in people with neurogenic dysphagia. Dysphagia. 2012;27:240–50.PubMedCrossRefGoogle Scholar
  95. 95.
    Mitchell JC, Counselman FL. A taste comparison of three different liquid steroid preparations: prednisone, prednisolone, and dexamethasone. Acad Emerg Med. 2003;10:400–3.PubMedCrossRefGoogle Scholar
  96. 96.
    Gee SC, Hagemann TM. Palatability of liquid anti-infectives: clinician and student perceptions and practice outcomes. J Pediatr Pharmacol Ther. 2007;12:216–23.PubMedPubMedCentralGoogle Scholar
  97. 97.
    Dantas RO, Kern MK, Massey BT, et al. Effect of swallowed bolus variables on oral and pharyngeal phases of swallowing. Am J Physiol. 1990;258:G675–81.PubMedGoogle Scholar
  98. 98.
    Reimers-Neils L, Logemann J, Larson C. Viscosity effects on EMG activity in normal swallow. Dysphagia. 1994;9:101–6.PubMedCrossRefGoogle Scholar
  99. 99.
    Steele CM, Van Lieshout PH. Influence of bolus consistency on lingual behaviors in sequential swallowing. Dysphagia. 2004;19:192–206.PubMedCrossRefGoogle Scholar
  100. 100.
    Troche MS, Sapienza CM, Rosenbek JC. Effects of bolus consistency on timing and safety of swallow in patients with Parkinson’s disease. Dysphagia. 2008;23:26–32.PubMedCrossRefGoogle Scholar
  101. 101.
    Logemann JA, Gensler G, Robbins J, et al. A randomized study of three interventions for aspiration of thin liquids in patients with dementia or Parkinson’s disease. J Speech Lang Hear Res. 2008;51:173–83.PubMedPubMedCentralCrossRefGoogle Scholar
  102. 102.
    Bisch EM, Logemann JA, Rademaker AW, et al. Pharyngeal effects of bolus volume, viscosity, and temperature in patients with dysphagia resulting from neurologic impairment and in normal subjects. J Speech Hear Res. 1994;37:1041–59.PubMedCrossRefGoogle Scholar
  103. 103.
    Rasley A, Logemann JA, Kahrilas PJ, et al. Prevention of barium aspiration during videofluoroscopic swallowing studies: value of change in posture. AJR Am J Roentgenol. 1993;160:1005–9.PubMedCrossRefGoogle Scholar
  104. 104.
    Logemann JA, Rademaker AW, Pauloski BR, et al. Effects of postural change on aspiration in head and neck surgical patients. Otolaryngol Head Neck Surg. 1994;110:222–7.PubMedCrossRefGoogle Scholar
  105. 105.
    Solazzo A, Monaco L, Del Vecchio L, et al. Investigation of compensatory postures with videofluoromanometry in dysphagia patients. World J Gastroenterol. 2012;18:2973–8.PubMedPubMedCentralCrossRefGoogle Scholar
  106. 106.
    Terre R, Mearin F. Effectiveness of chin-down posture to prevent tracheal aspiration in dysphagia secondary to acquired brain injury. A videofluoroscopy study. Neurogastroenterol Motil. 2012;24(414–9):e206.Google Scholar
  107. 107.
    Ohmae Y, Ogura M, Kitahara S, et al. Effects of head rotation on pharyngeal function during normal swallow. Ann Otol Rhinol Laryngol. 1998;107:344–8.PubMedCrossRefGoogle Scholar
  108. 108.
    Cohen R, Rocque F, Lécuyer A, et al. Study of the acceptability of antibiotic syrups, suspensions, and oral solutions prescribed to pediatric outpatients. Eur J Pediatr. 2009;168:851–7.PubMedCrossRefGoogle Scholar
  109. 109.
    Ernest TB, Elder DP, Martini LG, et al. Developing paediatric medicines: identifying the needs and recognizing the challenges. J Pharm Pharmacol. 2007;59:1043–55.PubMedCrossRefGoogle Scholar
  110. 110.
    Zampini M, Spence C. Assessing the role of visual and auditory cues in multisensory perception of flavor. In: Murray MM, Wallace MT, editors. The neural bases of multisensory processes. Boca Raton: CRC Press; 2012. Chapter 37. http://www.ncbi.nlm.nih.gov/books/NBK92852/. Accessed 18 Sep 2104.Google Scholar
  111. 111.
    Miller AJ. Deglutition. Physiol Rev. 1982;62:129–84.PubMedCrossRefGoogle Scholar
  112. 112.
    Bartoshuk LM. Taste. Robust across the age span? Ann N Y Acad Sci. 1989;561:65–75.PubMedCrossRefGoogle Scholar
  113. 113.
    Shabir Q, Skaria C, Brien H, et al. Taste and mouthfeel assessment of porous and non-porous silicon microparticles. Nanoscale Res Lett. 2012;7:1–6.CrossRefGoogle Scholar
  114. 114.
    Coster ST, Schwarz WH. Rheology and the swallow-safe bolus. Dysphagia. 1987;1:113–8.CrossRefGoogle Scholar
  115. 115.
    Leonard RJ, White C, McKenzie S, et al. Effects of bolus rheology on aspiration in patients with dysphagia. J Acad Nutr Diet. 2014;114(4):590–4.PubMedCrossRefGoogle Scholar
  116. 116.
    Morecroft CW, Caldwell NA, Gill A. Prescribing liquid medication: can the dose be accurately given? Arch Dis Child. 2013;98:831–2.PubMedCrossRefGoogle Scholar
  117. 117.
    Jones DV, Work CE. Volume of a swallow. Am J Dis Child. 1961;102:427.PubMedGoogle Scholar
  118. 118.
    Adnerhill I, Ekberg O, Groher ME. Determining normal bolus size for thin liquids. Dysphagia. 1989;4:1–3.PubMedCrossRefGoogle Scholar
  119. 119.
    Daniels SK, Corey DM, Hadskey LD, et al. Mechanism of sequential swallowing during straw drinking in healthy young and older adults. J Speech Lang Hear Res. 2004;47:33–45.PubMedCrossRefGoogle Scholar
  120. 120.
    Balou M, McCullough GH, Aduli F, et al. Manometric measures of head rotation and chin tuck in healthy participants. Dysphagia. 2014;29(1):25–32.PubMedCrossRefGoogle Scholar
  121. 121.
    Sakuma T, Kida I. Relationship between ease of swallowing and deglutition-related muscle activity in various postures. J Oral Rehabil. 2010;37:583–9.PubMedGoogle Scholar
  122. 122.
    Ekberg O. Posture of the head and pharyngeal swallowing. Acta Radiol Diagn (Stockh). 1986;27:691–6.CrossRefGoogle Scholar
  123. 123.
    Shanahan TK, Logemann JA, Rademaker AW, et al. Chin-down posture effect on aspiration in dysphagic patients. Arch Phys Med Rehabil. 1993;74:736–9.PubMedCrossRefGoogle Scholar
  124. 124.
    Welch MV, Logemann JA, Rademaker AW, et al. Changes in pharyngeal dimensions effected by chin tuck. Arch Phys Med Rehabil. 1993;74:178–81.PubMedGoogle Scholar
  125. 125.
    Logemann JA, Kahrilas PJ, Kobara M, et al. The benefit of head rotation on pharyngoesophageal dysphagia. Arch Phys Med Rehabil. 1989;70:767–71.PubMedGoogle Scholar
  126. 126.
    Motte J, Pedespan JM, Sevestre M, et al. Acceptability and tolerance of sodium valproate, a new sustained-action granule formulation, in monotherapy for epileptic children from 3 years old. Arch Pediatr. 2005;12:1533–9.PubMedCrossRefGoogle Scholar
  127. 127.
    Zlotkin S, Arthur P, Antwi KY, et al. Treatment of anemia with microencapsulated ferrous fumarate plus ascorbic acid supplied as sprinkles to complementary (weaning) foods. Am J Clin Nutr. 2001;74:791–5.PubMedCrossRefGoogle Scholar
  128. 128.
    Zlotkin S, Antwi KY, Schauer C, et al. Use of microencapsulated iron(II) fumarate sprinkles to prevent recurrence of anaemia in infants and young children at high risk. Bull World Health Organ. 2003;81:108–15.PubMedPubMedCentralGoogle Scholar
  129. 129.
    Hirve S, Bhave S, Bavdekar A, et al. Low dose ‘sprinkles’—an innovative approach to treat iron deficiency anemia in infants and young children. Indian Pediatr. 2007;44:91–100.PubMedGoogle Scholar
  130. 130.
    Adu-Afarwuah S, Lartey A, Brown KH, et al. Home fortification of complementary foods with micronutrient supplements is well accepted and has positive effects on infant iron status in Ghana. Am J Clin Nutr. 2008;87:929–38.PubMedCrossRefGoogle Scholar
  131. 131.
    Geltman PL, Hironaka LK, Mehta SD, et al. Iron supplementation of low-income infants: a randomized clinical trial of adherence with ferrous fumarate sprinkles versus ferrous sulfate drops. J Pediatr. 2009;154:738–43.PubMedCrossRefGoogle Scholar
  132. 132.
    den Uyl D, Geusens PP, van Berkum FN, et al. Patient preference and acceptability of calcium plus vitamin D3 supplementation: a randomised, open, cross-over trial. Clin Rheumatol. 2010;29:465–72.CrossRefGoogle Scholar
  133. 133.
    MacDonald A, Lilburn M, Davies P, et al. ‘Ready to drink’ protein substitute is easier is for people with phenylketonuria. J Inherit Metab Dis. 2006;29:526–31.PubMedCrossRefGoogle Scholar
  134. 134.
    Nasrin D, Larson CP, Sultana S, et al. Acceptability of and adherence to dispersible zinc tablet in the treatment of acute childhood diarrhoea. J Health Popul Nutr. 2005;23:215–21.PubMedGoogle Scholar
  135. 135.
    Winch PJ, Gilroy KE, Doumbia S, et al. Short report: prescription and administration of a 14-day regimen of zinc treatment for childhood diarrhea in Mali. Am J Trop Med Hyg. 2006;74:880–3.PubMedGoogle Scholar
  136. 136.
    Ameen VZ, Pobiner BF, Giguere GC, et al. Ranitidine (Zantac) syrup versus ranitidine effervescent tablets (Zantac) EFFERdose) in children: a single-center taste preference study. Paediatr Drugs. 2006;8:265–70.PubMedCrossRefGoogle Scholar
  137. 137.
    Bayer AJ, Day JJ, Finucane P, et al. Bioavailability and acceptability of a dispersible formulation of levodopa-benserazide in parkinsonian patients with and without dysphagia. J Clin Pharm Ther. 1988;13:191–4.PubMedCrossRefGoogle Scholar
  138. 138.
    Tolia V, Han C, North JD, et al. Taste comparisons for lansoprazole strawberry-flavoured delayed-release orally disintegrating tablet and ranitidine peppermint-flavoured syrup in children. Clin Drug Investig. 2005;25:285–92.PubMedCrossRefGoogle Scholar
  139. 139.
    Cohen IT, Joffe D, Hummer K, et al. Ondansetron oral disintegrating tablets: acceptability and efficacy in children undergoing adenotonsillectomy. Anesth Analg. 2005;101:59–63.PubMedCrossRefGoogle Scholar
  140. 140.
    Freedman SB, Adler M, Seshadri R, et al. Oral ondansetron for gastroenteritis in a pediatric emergency department. N Engl J Med. 2006;354:1698–705.PubMedCrossRefGoogle Scholar
  141. 141.
    Danileviciute V, Sveikata A, Adomaitiene V, et al. Efficacy, tolerability, and preference of mirtazapine orally disintegrating tablets in depressed patients: a 17-week naturalistic study in Lithuania. Medicina (Kaunas). 2009;45:778–84.Google Scholar
  142. 142.
    Wade AG, Crawford GM, Young D. A survey of patient preferences for a placebo orodispersible tablet. Patient Prefer Adherence. 2012;6:201–6.PubMedPubMedCentralCrossRefGoogle Scholar
  143. 143.
    Kinon BJ, Hill AL, Liu H, et al. Olanzapine orally disintegrating tablets in the treatment of acutely ill non-compliant patients with schizophrenia. Int J Neuropsychopharmacol. 2003;6:97–102.PubMedCrossRefGoogle Scholar
  144. 144.
    Nelson JC, Hollander SB, Betzel J, et al. Mirtazapine orally disintegrating tablets in depressed nursing home residents 85 years of age and older. Int J Geriatr Psychiatry. 2006;21:898–901.PubMedCrossRefGoogle Scholar
  145. 145.
    Nausieda PA. A multicenter, open-label, sequential study comparing preferences for carbidopa-levodopa orally disintegrating tablets and conventional tablets in subjects with Parkinson’s disease. Clin Ther. 2005;27:58–63.PubMedCrossRefGoogle Scholar
  146. 146.
    Michele TM, Knorr B, Vadas EB, et al. Safety of chewable tablets for children. J Asthma. 2002;39:391–403.PubMedCrossRefGoogle Scholar
  147. 147.
    Bukstein DA, Bratton DL, Firriolo KM, et al. Evaluation of parental preference for the treatment of asthmatic children aged 6 to 11 years with oral montelukast or inhaled cromolyn: a randomized, open-label, crossover study. J Asthma. 2003;40:475–85.PubMedCrossRefGoogle Scholar
  148. 148.
    Lazarus CL, Logemann JA, Rademaker AW, et al. Effects of bolus volume, viscosity, and repeated swallows in nonstroke subjects and stroke patients. Arch Phys Med Rehabil. 1993;74:1066–70.PubMedCrossRefGoogle Scholar
  149. 149.
    Lee KL, Kim WH, Kim EJ, et al. Is swallowing of all mixed consistencies dangerous for penetration-aspiration? Am J Phys Med Rehabil. 2012;91:187–92.PubMedCrossRefGoogle Scholar
  150. 150.
    Tsukada T, Taniguchi H, Ootaki S, et al. Effects of food texture and head posture on oropharyngeal swallowing. J Appl Physiol. 1985;2009(106):1848–57.Google Scholar
  151. 151.
    World Health Organization. Development of paediatric medicines: points to consider in pharmaceutical development (Working document QAS/08.257/Rev.3), 2012. http://www.who.int/medicines/areas/quality_safety/quality_assurance/Rev3-PaediatricMedicinesDevelopment_QAS08-257Rev3_17082011.pdf. Accessed 18 Sep 2014.
  152. 152.
    Gerrard SE, Orlu-Gul M, Tuleu C, et al. Modeling the physiological factors that affect drug delivery from a nipple shield delivery system to breastfeeding infants. J Pharm Sci. 2013;102:3773–83.PubMedCrossRefGoogle Scholar
  153. 153.
    Dessirier JM, Simons CT, Carstens MI, et al. Psychophysical and neurobiological evidence that the oral sensation elicited by carbonated water is of chemogenic origin. Chem Senses. 2000;25:277–84.PubMedCrossRefGoogle Scholar
  154. 154.
    Maguire A, Baqir W, Nunn JH. Are sugars-free medicines more erosive than sugars-containing medicines? An in vitro study of paediatric medicines with prolonged oral clearance used regularly and long-term by children. Int J Paediatr Dent. 2007;17:231–8.PubMedCrossRefGoogle Scholar
  155. 155.
    George J, Majeed W, Mackenzie IS, et al. Association between cardiovascular events and sodium-containing effervescent, dispersible, and soluble drugs: nested case–control study. BMJ. 2013;347:f6954.PubMedPubMedCentralCrossRefGoogle Scholar
  156. 156.
    Ubeda A, Llopico J, Sanchez MT. Blood pressure reduction in hypertensive patients after withdrawal of effervescent medication. Pharmacoepidemiol Drug Saf. 2009;18:417–9.PubMedCrossRefGoogle Scholar
  157. 157.
    Carnaby-Mann G, Crary M. Pill swallowing by adults with dysphagia. Arch Otolaryngol Head Neck Surg. 2005;131:970–5.PubMedCrossRefGoogle Scholar
  158. 158.
    Montgomery W, Treuer T, Karagianis J, et al. Orally disintegrating olanzapine review: effectiveness, patient preference, adherence, and other properties. Patient Prefer Adherence. 2012;6:109–25.PubMedPubMedCentralCrossRefGoogle Scholar
  159. 159.
    Gupta A, Chidambaram N, Khan MA. An index for evaluating difficulty of chewing the chewable tablets. Drug Dev Ind Pharm. Epub 2013 Nov 19.Google Scholar
  160. 160.
    Food and Drug Administration (FDA). Guidance for industry size of beads in drug products labeled for sprinkle, 2012. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM240243.pdf. Accessed 11 Jul 2014.
  161. 161.
    An alternative medicine treatment for Parkinson’s disease: results of a multicenter clinical trial. HP-200 in Parkinson’s Disease Study Group. J Altern Complement Med. 1995;1:249–55.Google Scholar
  162. 162.
    Baqir W, Maguire A. Consumption of prescribed and over-the-counter medicines with prolonged oral clearance used by the elderly in the Northern Region of England, with special regard to generic prescribing, dose form and sugars content. Public Health. 2000;114:367–73.PubMedCrossRefGoogle Scholar
  163. 163.
    Keith S. Advances in psychotropic formulations. Prog Neuropsychopharmacol Biol Psychiatry. 2006;30:996–1008.PubMedCrossRefGoogle Scholar
  164. 164.
    Muramatsu RS, Litzinger MH, Fisher E, et al. Alternative formulations, delivery methods, and administration options for psychotropic medications in elderly patients with behavioral and psychological symptoms of dementia. Am J Geriatr Pharmacother. 2010;8:98–114.PubMedCrossRefGoogle Scholar
  165. 165.
    Delaney AL, Rudolph C. Nascent oral phase. In: Shaker R, Belafsky PC, Postma GN, et al., editors. Principles of deglutition. New York: Springer; 2013.Google Scholar
  166. 166.
    Kida IA, Astrom AN, Strand GV, et al. Chewing problems and dissatisfaction with chewing ability: a survey of older Tanzanians. Eur J Oral Sci. 2007;115:265–74.PubMedCrossRefGoogle Scholar
  167. 167.
    Peltola P, Vehkalahti MM. Chewing ability of the long-term hospitalized elderly. Spec Care Dentist. 2005;25:260–4.PubMedCrossRefGoogle Scholar
  168. 168.
    Yoshioka M, Hinode D, Yokoyama M, et al. Relationship between subjective oral health status and lifestyle in elderly people: a cross-sectional study in Japan. ISRN Dent. 2013;2013:687139.PubMedPubMedCentralGoogle Scholar
  169. 169.
    Avlund K, Holm-Pedersen P, Schroll M. Functional ability and oral health among older people: a longitudinal study from age 75 to 80. J Am Geriatr Soc. 2001;49:954–62.PubMedCrossRefGoogle Scholar
  170. 170.
    Okabe H, Suzuki E, Sugiura Y, et al. Development of an easily swallowed film formulation. Int J Pharm. 2008;355:62–6.PubMedCrossRefGoogle Scholar
  171. 171.
    Cassolato SF, Turnbull RS. Xerostomia: clinical aspects and treatment. Gerodontology. 2003;20:64–77.PubMedCrossRefGoogle Scholar
  172. 172.
    Imai K. Alendronate sodium hydrate (oral jelly) for the treatment of osteoporosis: review of a novel, easy to swallow formulation. Clin Interv Aging. 2013;8:681–8.PubMedPubMedCentralCrossRefGoogle Scholar
  173. 173.
    Doesch AO, Mueller S, Konstandin M, et al. Increased adherence after switch from twice daily calcineurin inhibitor based treatment to once daily modified released tacrolimus in heart transplantation: a pre-experimental study. Transplant Proc. 2010;42:4238–42.PubMedCrossRefGoogle Scholar
  174. 174.
    Portsmouth SD, Osorio J, McCormick K, et al. Better maintained adherence on switching from twice-daily to once-daily therapy for HIV: a 24-week randomized trial of treatment simplification using stavudine prolonged-release capsules. HIV Med. 2005;6:185–90.PubMedCrossRefGoogle Scholar
  175. 175.
    Schier JG, Howland MA, Hoffman RS, et al. Fatality from administration of labetalol and crushed extended-release nifedipine. Ann Pharmacother. 2003;37:1420–3.PubMedCrossRefGoogle Scholar
  176. 176.
    Vergote GJ, Vervaet C, Van Driessche I, et al. An oral controlled release matrix pellet formulation containing nanocrystalline ketoprofen. Int J Pharm. 2001;219:81–7.PubMedCrossRefGoogle Scholar
  177. 177.
    Yamada T, Onishi H, Machida Y. Sustained release ketoprofen microparticles with ethylcellulose and carboxymethylethylcellulose. J Control Release. 2001;75:271–82.PubMedCrossRefGoogle Scholar
  178. 178.
    Lopes CM, Lobo JM, Pinto JF, et al. Compressed matrix core tablet as a quick/slow dual-component delivery system containing ibuprofen. AAPS PharmSciTech. 2007;8:E76.PubMedCrossRefGoogle Scholar
  179. 179.
    Shimokawa K, Saegusa K, Wada Y, et al. Physicochemical properties and controlled drug release of microcapsules prepared by simple coacervation. Colloids Surf B Biointerfaces. 2013;104:1–4.PubMedCrossRefGoogle Scholar
  180. 180.
    Abdul S, Chandewar AV, Jaiswal SB. A flexible technology for modified-release drugs: multiple-unit pellet system (MUPS). J Control Release. 2010;147:2–16.PubMedCrossRefGoogle Scholar
  181. 181.
    Wilson JT, Helms R, Pickering BD, et al. Acetaminophen controlled-release sprinkles versus acetaminophen immediate-release elixir in febrile children. J Clin Pharmacol. 2000;40:360–9.PubMedCrossRefGoogle Scholar
  182. 182.
    Pensi T. Fixed dose combination of lamivudine, stavudine and nevirapine in the treatment of pediatric HIV infection: a preliminary report. Indian Pediatr. 2007;44:519–21.PubMedGoogle Scholar
  183. 183.
    Kayitare E, Vervaet C, Ntawukulilyayo JD, et al. Development of fixed dose combination tablets containing zidovudine and lamivudine for paediatric applications. Int J Pharm. 2009;370:41–6.PubMedCrossRefGoogle Scholar

Copyright information

© The Author(s) 2014

Open AccessThis article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.

Authors and Affiliations

  • Fang Liu
    • 1
  • Sejal Ranmal
    • 2
  • Hannah K. Batchelor
    • 3
  • Mine Orlu-Gul
    • 2
  • Terry B. Ernest
    • 4
  • Iwan W. Thomas
    • 5
  • Talia Flanagan
    • 6
  • Catherine Tuleu
    • 2
  1. 1.Department of Pharmacy, School of Life and Medical SciencesUniversity of HertfordshireHatfieldUK
  2. 2.Department of PharmaceuticsUCL School of Pharmacy, University College LondonLondonUK
  3. 3.Pharmacy, Pharmacology and Therapeutics, School of Clinical and Experimental Medicine, College of Medical and Dental SciencesUniversity of BirminghamBirminghamUK
  4. 4.GlaxoSmithKlineHarlowUK
  5. 5.Piramal Healthcare UK LtdMorpethUK
  6. 6.Pharmaceutical Development, AstraZenecaMacclesfieldUK

Personalised recommendations